跳至主要内容
临床试验/NCT00231387
NCT00231387已完成3 期

Rosiglitazone and Plaque Study: A 12 Month Randomised, Double-blind, Placebo-controlled, Magnetic Resonance Imaging Study to Evaluate the Effect of Rosiglitazone on the Structure and Composition of Carotid Atherosclerotic Plaques in Subjects With Type 2 Diabetes Mellitus and Coexisting Vascular Disease or Hypertension

GlaxoSmithKline2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2002年9月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
60
试验地点
2
主要终点
The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri.

研究概览

简要总结

This is a phase IIIb, randomised, double blind, placebo controlled, study in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension. The total duration of the study will be approximately 60 weeks. The aim of this study is to examine the potential beneficial effects of rosiglitazone on carotid atheroma in patients with type 2 diabetes mellitus and coexisting vascular disease or hypertension. It is hypothesised that treatment with rosiglitazone will lead to an decrease in plaque size. In addition, it is hoped that rosiglitazone will have a positive effect on plaque composition and stability.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
30 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes.
  • Co-existing vascular disease.
  • At least 6 months of statin or fibrate therapy.
  • HbA1c <10% at screening and with at least one atheromatous plaque causing 10-95% narrowing of the internal carotid artery.

排除标准

  • Patients with >2 concomitant oral anti-hyperglycaemic agents within 3 months of screening.
  • Previous exposure to a thiazolidinedione.
  • History of chronic insulin use.
  • Use of investigational drug within 30 days.
  • Systolic blood pressure (bp) > 170 mmHg or diastolic bp >100 mmHg.
  • Severe or unstable angina.
  • History of: gangrene, TIA, stroke, hepatic disease, alcohol or drug abuse, surgery of the carotid arteries or claustrophobia.

结局指标

主要结局

The effect of 52 wks oral treatment with rosiglitazone in comparison to placebo on change from baseline of the plaque total wall volume in the carotid artery, in patients with type 2 dm and vascular disease/hypertension, using cardiac mri.

时间窗: 52 Weeks

次要结局

  • These include magnetic resonance endpoints related to plaque lipid content, volume, plaque size and fibrous cap thickness. Colour duplex measurements, laboratory assays for glycaemia and lipids.

研究者

申办方类型
Industry

研究点 (2)

Loading locations...

相似试验